SCHEMBL5368470

SCHEMBL5368470

O=C1c2cccc(N3CCNCC3)c2Oc2ccc(F)cc2N1Cc1cccc(O)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.79
EGFR P00533 4/20 0.45
UBE2N P61088 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 4/20 0.40
POLB P06746 2/20 0.37
HTR7 P34969 1/20 0.36
HPGD P15428 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ALDH3A1 P30838 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
HTR1A P08908 1/20 0.36
SLC6A2 P23975 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364715 0.91 HTR6 (0.82) HTR6EGFRUBE2NTDP1LMNA
SCHEMBL5366734 0.90 HTR6 (0.64) HTR6EGFRSMN1; SMN2HTR1ASLC6A2
SCHEMBL5360955 0.90 HTR6 (0.80) HTR6EGFRUBE2NTDP1LMNA
SCHEMBL5364738 0.89 HTR6 (0.79) HTR6EGFRUBE2NTDP1LMNA
SCHEMBL5362910 0.89 HTR6 (1.00) HTR6EGFRUBE2NTDP1LMNA
SCHEMBL5366505 0.86 HTR6 (0.74) HTR6EGFRUBE2NTDP1LMNA
SCHEMBL5356843 0.83 HTR6 (0.70) HTR6EGFRUBE2NTDP1LMNA
SCHEMBL5364868 0.82 HTR6 (0.69) HTR6EGFRUBE2NTDP1LMNA
SCHEMBL5361156 0.82 HTR6 (0.68) HTR6EGFRUBE2NLMNAHTR7
SCHEMBL5372213 0.81 HTR6 (0.68) HTR6LMNAHPGDMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US claimed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US claimed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-7229984-B2 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2007-06-12 US disclosed
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof ROCHE PALO ALTO LLC 2006-07-13 US disclosed
WO-2006061126-A2 DIBENZOXAZEPINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154914-A1 Dibenzoxazepinone derivatives and uses thereof HTR6, BDKRB1, HTR7 HTR6 1/4885EGFR 1718/4885UBE2N 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.